Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C
Background/Purpose: The assessment of drug–drug interaction (DDI) is important not only for safety but also for maintaining the efficacy of direct acting antivirals in chronic hepatitis C (CHC). This study aims to evaluate DDI before and during elbasvir/grazoprevir (EBR/GZR) treatment. Methods: CHC...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-05-01
|
Series: | Journal of the Formosan Medical Association |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664619306667 |
id |
doaj-18093c28cc9a41b09ed20d122f1fb5df |
---|---|
record_format |
Article |
spelling |
doaj-18093c28cc9a41b09ed20d122f1fb5df2020-11-25T02:58:54ZengElsevierJournal of the Formosan Medical Association0929-66462020-05-011195933940Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis CChun-Jen Liu0Kuo-Chih Tseng1Ching-Chu Lo2I-Hao Tseng3Pin-Nan Cheng4Department of Internal Medicine, National Taiwan University, Hospital, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine Taipei, TaiwanDivision of Gastroenterology, Department of Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi; School of Medicine, Tzu Chi University, Hualien, TaiwanDepartment of Internal Medicine, St. Martin de Porres Hospital, Chia-Yi, TaiwanDepartment of Internal Medicine, Yuan's General Hospital, Kaohsiung, TaiwanDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Corresponding author. Department of Internal medicine, National Cheng Kung University Hospital, 138 Sheng-Li Road, Tainan, 704, Taiwan. Fax: +886 6 2081635.Background/Purpose: The assessment of drug–drug interaction (DDI) is important not only for safety but also for maintaining the efficacy of direct acting antivirals in chronic hepatitis C (CHC). This study aims to evaluate DDI before and during elbasvir/grazoprevir (EBR/GZR) treatment. Methods: CHC patients who treated with EBR/GZR in five hospitals were enrolled. The patients' demographic data, comorbidities, concomitant medications taken before and during EBR/GZR were recorded. DDI was evaluated using a tool from the HEP Drug Interactions (www.hep-druginteractions.org) website. In addition to the evaluation of DDI for EBR/GZR, the virtual DDI of ledipasvir/sofosbuvir (LDV/SOF), sofosbuvir/velpatasvir (SOF/VEL) and glecaprevir/pibrentasvir (GLE/PIB) were evaluated. Degrees of DDI were classified as “do not co-administer”, “potential interaction”, and “potentially weak interaction”. Results: A total of 460 patients were enrolled. At baseline, 80.1% of patients had one or more comorbidities and 72.8% took one or more medications. Cardiovascular diseases (43.9%), gastrointestinal diseases (37.4%), and metabolic diseases (36.7%) were the three most common comorbidities. The prevalence of DDI before EBR/GZR treatment was 12.8% (59 patients). Among the same population, the prevalence of virtual DDI of SOF/VEL, GLE/PIB, and LDV/SOF were 38.5% (179 patients), 48.8% (220 patients), and 57.0% (262 patients), respectively. During EBR/GZR treatment, 167 patients (36.3%) took newly prescribed medications. One patient (0.2%) and seven patients (1/5%) exhibited do-not-co-administer and potential interaction with EBR/GZR, respectively. Conclusion: DDI was limited in treatment with EBR/GZR. DDI can occur upon the administering of a new medication during antiviral treatment and attention should be paid to it. Trial registration number: NCT03706222.http://www.sciencedirect.com/science/article/pii/S0929664619306667Drug–drug interactionDirect acting antiviralsElbasvir/grazoprevir |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chun-Jen Liu Kuo-Chih Tseng Ching-Chu Lo I-Hao Tseng Pin-Nan Cheng |
spellingShingle |
Chun-Jen Liu Kuo-Chih Tseng Ching-Chu Lo I-Hao Tseng Pin-Nan Cheng Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C Journal of the Formosan Medical Association Drug–drug interaction Direct acting antivirals Elbasvir/grazoprevir |
author_facet |
Chun-Jen Liu Kuo-Chih Tseng Ching-Chu Lo I-Hao Tseng Pin-Nan Cheng |
author_sort |
Chun-Jen Liu |
title |
Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C |
title_short |
Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C |
title_full |
Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C |
title_fullStr |
Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C |
title_full_unstemmed |
Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C |
title_sort |
limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis c |
publisher |
Elsevier |
series |
Journal of the Formosan Medical Association |
issn |
0929-6646 |
publishDate |
2020-05-01 |
description |
Background/Purpose: The assessment of drug–drug interaction (DDI) is important not only for safety but also for maintaining the efficacy of direct acting antivirals in chronic hepatitis C (CHC). This study aims to evaluate DDI before and during elbasvir/grazoprevir (EBR/GZR) treatment. Methods: CHC patients who treated with EBR/GZR in five hospitals were enrolled. The patients' demographic data, comorbidities, concomitant medications taken before and during EBR/GZR were recorded. DDI was evaluated using a tool from the HEP Drug Interactions (www.hep-druginteractions.org) website. In addition to the evaluation of DDI for EBR/GZR, the virtual DDI of ledipasvir/sofosbuvir (LDV/SOF), sofosbuvir/velpatasvir (SOF/VEL) and glecaprevir/pibrentasvir (GLE/PIB) were evaluated. Degrees of DDI were classified as “do not co-administer”, “potential interaction”, and “potentially weak interaction”. Results: A total of 460 patients were enrolled. At baseline, 80.1% of patients had one or more comorbidities and 72.8% took one or more medications. Cardiovascular diseases (43.9%), gastrointestinal diseases (37.4%), and metabolic diseases (36.7%) were the three most common comorbidities. The prevalence of DDI before EBR/GZR treatment was 12.8% (59 patients). Among the same population, the prevalence of virtual DDI of SOF/VEL, GLE/PIB, and LDV/SOF were 38.5% (179 patients), 48.8% (220 patients), and 57.0% (262 patients), respectively. During EBR/GZR treatment, 167 patients (36.3%) took newly prescribed medications. One patient (0.2%) and seven patients (1/5%) exhibited do-not-co-administer and potential interaction with EBR/GZR, respectively. Conclusion: DDI was limited in treatment with EBR/GZR. DDI can occur upon the administering of a new medication during antiviral treatment and attention should be paid to it. Trial registration number: NCT03706222. |
topic |
Drug–drug interaction Direct acting antivirals Elbasvir/grazoprevir |
url |
http://www.sciencedirect.com/science/article/pii/S0929664619306667 |
work_keys_str_mv |
AT chunjenliu limiteddrugdruginteractionofelbasvirgrazoprevirforchronichepatitisc AT kuochihtseng limiteddrugdruginteractionofelbasvirgrazoprevirforchronichepatitisc AT chingchulo limiteddrugdruginteractionofelbasvirgrazoprevirforchronichepatitisc AT ihaotseng limiteddrugdruginteractionofelbasvirgrazoprevirforchronichepatitisc AT pinnancheng limiteddrugdruginteractionofelbasvirgrazoprevirforchronichepatitisc |
_version_ |
1724704605180264448 |